Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus

• Published in: Transplantation Vol. 77; no. 7; p. 1066
• Main Authors: Bozorgzadeh, Adel, Jain, Ashok, Ryan, Charlotte, Ornt, Daniel, Zand, Martin, Mantry, Parvez, Lansing, Kerrie, Orloff, Mark
• Format: Journal Article
• Language: English
• Published: United States 15.04.2004
• Subjects: Adult; Aged; Cadaver; Cause of Death; Graft Survival; Hepatitis C - mortality; Hepatitis C - surgery; Humans; Immunosuppressive Agents - therapeutic use; Liver Transplantation; Living Donors; Middle Aged; Recurrence; Retrospective Studies; Tacrolimus - therapeutic use; Transplantation, Homologous
• ISSN: 0041-1337
• DOI: 10.1097/01.tp.0000122142.00818.9e

There has been concern that adult living-donor liver transplantation (LLTx) for hepatitis C virus (HCV) infection may lead to recurrent disease that is more severe compared with the results of cadaveric LTx (CLTx), because the smaller sized graft in LLTx regenerates and may increase viral replication. This study examines the survival outcome and HCV recurrence in CLTx versus LLTx performed at a single institution. A total of 100 consecutive adult recipients (75 men and 25 women; mean age 49.9+/-8.4 years) of LTx (65 CLTxs and 35 LLTxs performed July 2000-July 2002) who tested positive for HCV by polymerase chain reaction were examined retrospectively until October 2003. All patients received tacrolimus-based immunosuppression with mycophenolate mofetil and steroids. The overall actual patient survival was 85% (83.1% for CLTx vs. 88.6% for LLTx). The 39-month Kaplan-Meier actuarial patient survivals were 75.1% for CLTx and 88.6% for LLTx. Of 15 deaths, 6 were the result of recurrent HCV (five CLTxs and one LLTx), and of 10 retransplants, 2 were related to recurrent HCV (one CLTx and one LLTx). The rates of recurrence were 72.3% and 77.1%, the hepatitis activity indices were 5.4 + 2.4 and 6.2 + 2.8, the fibrosis scores were 1.4+/-1.4 and 1.5+/-1.3, and the times to recurrence were 318+/-269 days and 394+/-250 days for CLTx and LLTx, respectively. None of the differences between the two groups were significant. No detrimental effect of HCV infection was found in LLTx recipients when compared with contemporaneous CLTx recipients. Patient survival, graft survival, rate of HCV recurrence, severity of HCV recurrence, graft loss from HCV, and interval for recurrence in CLTx and LLTx were similar.